Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Reiffers, A. Stoppa, M. Attal, M. Michallet, G. Marit, D. Blaise, F. Huguet, B. Corront, P. Cony-Makhoul, J. Gastaut, Guy Laurent, L. Molina, A. Broustet, D. Maraninchi, J. Pris, D. Hollard, C. Faberes (1996)Allogeneic vs autologous stem cell transplantation vs chemotherapy in patients with acute myeloid leukemia in first remission: the BGMT 87 study.
Leukemia, 10 12
P. Fenaux, G. Mufti, E. Hellstrom-Lindberg, V. Santini, C. Finelli, A. Giagounidis, R. Schoch, N. Gattermann, G. Sanz, A. List, S. Gore, J. Seymour, J. Bennett, J. Byrd, J. Backstrom, L. Zimmerman, D. McKenzie, C. Beach, L. Silverman (2009)Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.
The Lancet. Oncology, 10 3
G. Garcia-Manero (2012)Myelodysplastic syndromes: 2012 update on diagnosis, risk‐stratification, and management
American Journal of Hematology, 87
M. Extermann, I. Boler, R. Reich, G. Lyman, Richard Brown, J. Defelice, R. Levine, E. Lubiner, P. Reyes, F. Schreiber, L. Balducci (2012)Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High‐Age Patients (CRASH) score
A. Raza, J. Reeves, E. Feldman, G. Dewald, John Bennett, H. Deeg, L. Dreisbach, C. Schiffer, R. Stone, P. Greenberg, P. Curtin, V. Klimek, J. Shammo, Deborah Thomas, R. Knight, Michele Schmidt, K. Wride, J. Zeldis, A. List (2008)Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.
Blood, 111 1
A. Hurria, K. Togawa, S. Mohile, C. Owusu, H. Klepin, C. Gross, S. Lichtman, A. Gajra, S. Bhatia, V. Katheria, S. Klapper, K. Hansen, R. Ramani, M. Lachs, F. Wong, W. Tew (2011)Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 25
R. Bejar, K. Stevenson, O. Abdel-Wahab, N. Galili, B. Nilsson, G. Garcia-Manero, H. Kantarjian, A. Raza, R. Levine, D. Neuberg, B. Ebert (2011)Clinical effect of point mutations in myelodysplastic syndromes.
The New England journal of medicine, 364 26
W. Blum, R. Garzon, R. Klisovic, S. Schwind, A. Walker, S. Geyer, Shujun Liu, V. Havelange, H. Becker, L. Schaaf, J. Mickle, H. Devine, C. Kefauver, S. Devine, K. Chan, N. Heerema, C. Bloomfield, M. Grever, J. Byrd, M. Villalona-Calero, C. Croce, G. Marcucci (2010)Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine
Proceedings of the National Academy of Sciences, 107
C. Cutler, Stephanie Lee, P. Greenberg, H. Deeg, W. Pérez, C. Anasetti, B. Bolwell, M. Cairo, R. Gale, J. Klein, H. Lazarus, J. Liesveld, P. McCarthy, G. Milone, J. Rizzo, K. Schultz, M. Trigg, A. Keating, D. Weisdorf, J. Antin, M. Horowitz (2004)A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome.
Blood, 104 2
A. Raza, N. Galili (2012)The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes
Nature Reviews Cancer, 12
E. Atallah, T. Pedersen, E. Warlick, Anne Dircks, D. Weisdorf, M. Horowitz, J. Rizzo (2012)The Outcome of Hematopoietic Cell Transplantation (HCT) for Myelodysplastic Syndrome (MDS) in Adults ≥65 Years of Age: First Report of the Coverage with Evidence Development (CED) in Medicare Beneficiaries
A. Burnett, R. Hills, D. Milligan, A. Goldstone, A. Prentice, M. McMullin, A. Duncombe, B. Gibson, K. Wheatley (2010)Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 4
C. Cogle, Benjamin Craig, D. Rollison, A. List (2011)Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries.
Blood, 117 26
R. Arceci (2011)Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias
Yearbook of Oncology, 2011
Dr. Nurul, Akhtar Hasan, Mohammad Mamun (1997)Leading article
E Atallah, TL Pedersen, ED Warlick, A Dircks, D Weisdorf, MM Horowitz (2012)The outcome of Hematopoietic Cell Transplantation (HCT) for Myelodysplastic Syndrome (MDS) in adults >=65 years of age: first report of the Coverage with Evidence Development (CED) in medicare beneficiaries
ASH Annual Meeting Abstracts, 120
U Platzbecker, M Wermke, J Radke, U Oelschlaegel, F Seltmann, A Kiani (2012)Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
D. Hiwase, D. Hiwase, D. Hiwase, C. Hahn, Milena Babic, S. Moore, C. Butcher, M. Kutyna, D. Singhal, Jinghua Feng, B. To, B. To, A. Schreiber, H. Scott (2014)Clonal Diversity of Recurrently Mutated Genes in Myelodysplastic Syndromes
X Ma, M Does, A Raza, ST Mayne (2007)Myelodysplastic syndromes: incidence and survival in the United States
K. Wheatley, R. Gray (2004)Commentary: Mendelian randomization--an update on its use to evaluate allogeneic stem cell transplantation in leukaemia.
International journal of epidemiology, 33 1
R. Kanesvaran, Huihua Li, K. Koo, D. Poon (2011)Analysis of prognostic factors of comprehensive geriatric assessment and development of a clinical scoring system in elderly Asian patients with cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 27
M. Walter, D. Shen, J. Shao, Li Ding, Brian White, C. Kandoth, Christopher Miller, Beifang Niu, M. McLellan, N. Dees, Robert Fulton, Kevin Elliot, S. Heath, Marcus Grillot, P. Westervelt, D. Link, J. Dipersio, E. Mardis, T. Ley, Richard Wilson, T. Graubert (2013)Clonal diversity of recurrently mutated genes in myelodysplastic syndromes
M Lubbert, S Suciu, L Baila, BH Ruter, U Platzbecker, A Giagounidis (2011)Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group
J Clin Oncol, 29
D. Weisdorf, S. Spellman, M. Haagenson, M. Horowitz, Stephanie Lee, C. Anasetti, M. Setterholm, R. Drexler, M. Maiers, R. King, D. Confer, J. Klein (2007)Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 14 7
L. Malcovati, U. Germing, A. Kuendgen, M. Porta, C. Pascutto, R. Invernizzi, A. Giagounidis, B. Hildebrandt, P. Bernasconi, S. Knipp, C. Strupp, M. Lazzarino, C. Aul, M. Cazzola (2007)Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 23
R. Nakamura, R. Rodríguez, J. Palmer, A. Stein, A. Naing, N. Tsai, K. Chang, M. Slovak, Ravi Bhatia, R. Spielberger, N. Kogut, V. Pullarkat, M. Kirschbaum, Stephen Forman, M. O'donnell (2007)Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome
Bone Marrow Transplantation, 40
P. Armand, Haesook Kim, J. Rhodes, Marie‐Michele Sainvil, C. Cutler, V. Ho, J. Koreth, E. Alyea, Doreen Hearsey, E. Neufeld, M. Fleming, H. Steen, Damon Anderson, R. Kwong, R. Soiffer, J. Antin (2011)Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 17 6
B. Mcclune, D. Weisdorf, T. Pedersen, Gisela Silva, M. Tallman, J. Sierra, J. Dipersio, A. Keating, R. Gale, B. George, Vikas Gupta, T. Hahn, L. Isola, M. Jagasia, H. Lazarus, D. Marks, R. Maziarz, E. Waller, C. Bredeson, S. Giralt (2010)Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 11
B. Scott, B. Storer, M. Loken, R. Storb, F. Appelbaum, H. Deeg (2005)Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 11 1
S. Goldberg, E. Chen, M. Corral, A. Guo, N. Mody-Patel, A. Pecora, M. Laouri (2010)Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 17
P. Greenberg, H. Tuechler, J. Schanz, G. Sanz, G. Garcia-Manero, F. Solé, J. Bennett, D. Bowen, P. Fenaux, F. Dreyfus, H. Kantarjian, A. Kuendgen, A. Levis, L. Malcovati, M. Cazzola, J. Čermák, C. Fonatsch, M. Beau, M. Slovak, O. Krieger, M. Luebbert, J. Maciejewski, S. Magalhães, Y. Miyazaki, M. Pfeilstöcker, M. Sekeres, W. Sperr, R. Stauder, S. Tauro, P. Valent, T. Vallespí, A. Loosdrecht, U. Germing, D. Haase (2012)Revised international prognostic scoring system for myelodysplastic syndromes.
Blood, 120 12
B. Deschler, G. Ihorst, U. Platzbecker, U. Germing, E. März, Marcelo Figuerido, K. Fritzsche, P. Haas, H. Salih, A. Giagounidis, D. Selleslag, B. Labar, T. Witte, P. Wijermans, M. Lübbert (2013)Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome
D. Steensma, M. Baer, J. Slack, R. Buckstein, L. Godley, G. Garcia-Manero, M. Albitar, J. Larsen, S. Arora, M. Cullen, H. Kantarjian (2009)Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 23
T. Field, J. Perkins, Y. Huang, M. Kharfan-Dabaja, M. Alsina, E. Ayala, H. Fernandez, W. Janssen, J. Lancet, L. Perez, D. Sullivan, A. List, C. Anasetti (2010)5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation
Bone Marrow Transplantation, 45
R Bejar, KE Stevenson, P Stojanov, JE Zaneveld, M Bar-Natan, B Caughey (2012)Detection of recurrent mutations by pooled targeted next-generation sequencing in MDS patients prior to treatment with hypomethylating agents or stem cell transplantation
ASH Annual Meeting Abstracts, 120
D. Rollison, N. Howlader, Martyn Smith, S. Strom, W. Merritt, L. Ries, B. Edwards, A. List (2008)Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs.
Blood, 112 1
M. Rodin, S. Mohile (2007)A practical approach to geriatric assessment in oncology.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 14
L. Muffly, M. Boulukos, Kate Swanson, M. Kocherginsky, P. Cerro, Linda Schroeder, L. Pape, M. Extermann, K. Besien, A. Artz (2013)Pilot study of comprehensive geriatric assessment (CGA) in allogeneic transplant: CGA captures a high prevalence of vulnerabilities in older transplant recipients.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 19 3
P. Greenberg, C. Cox, M. Lebeau, P. Fenaux, P. Morel, G. Sanz, M. Sanz, T. Vallespí, T. Hamblin, D. Oscier, K. Ohyashiki, K. Toyama, C. Aul, G. Mufti, John Bennett (1997)International scoring system for evaluating prognosis in myelodysplastic syndromes.
Blood, 89 6
L. Adès, S. Boehrer, T. Prebet, O. Beyne-Rauzy, L. Legros, C. Ravoet, F. Dreyfus, A. Stamatoullas, M. Chaury, J. Delaunay, G. Laurent, N. Vey, S. Burcheri, R. M’bida, N. Hoarau, C. Gardin, P. Fenaux (2009)Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study.
Blood, 113 17
BL Scott, HJ Deeg (2010)Myelodysplastic syndromes
Annu Rev Med, 61
R. Itzykson, S. Thépot, B. Quesnel, F. Dreyfus, O. Beyne-Rauzy, P. Turlure, N. Vey, C. Récher, C. Dartigeas, L. Legros, J. Delaunay, C. Salanoubat, Sorin Visanica, A. Stamatoullas, F. Isnard, A. Marfaing‐Koka, S. Botton, Y. Chelghoum, A. Taksin, I. Plantier, S. Amé, S. Boehrer, C. Gardin, C. Beach, L. Adès, P. Fenaux (2011)Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.
Blood, 117 2
B. Oran, S. Giralt, R. Saliba, C. Hosing, U. Popat, I. Khouri, D. Couriel, M. Qazilbash, P. Anderlini, P. Kebriaei, S. Ghosh, A. Carrasco-Yalan, E. Meis, A. Anagnostopoulos, M. Donato, R. Champlin, M. Lima (2007)Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 13 4
L. Malcovati, M. Porta, C. Pascutto, R. Invernizzi, M. Boni, E. Travaglino, F. Passamonti, L. Arcaini, M. Maffioli, P. Bernasconi, M. Lazzarino, M. Cazzola (2005)Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 30
P. Caillet, F. Canoui-Poitrine, J. Vouriot, M. Berle, N. Reinald, S. Krypciak, S. Bastuji‐Garin, S. Culine, E. Paillaud (2011)Comprehensive geriatric assessment in the decision-making process in elderly patients with cancer: ELCAPA study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 27
PL Greenberg, E Attar, JM Bennett, CD Bloomfield, U Borate, CM Castro (2013)Myelodysplastic syndromes
J Natl Compr Canc Netw, 11
W Blum, R Garzon, RB Klisovic, S Schwind, A Walker, S Geyer (2010)Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine
Proc Natl Acad Sci U S A, 107
H Kantarjian, JP Issa, CS Rosenfeld, JM Bennett, M Albitar, J DiPersio (2006)Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study
Z. Lim, V. Fiaccadori, S. Gandhi, J. Hayden, M. Kenyon, R. Ireland, J. Marsh, A. Ho, G. Mufti, A. Pagliuca (2010)Impact of pre-transplant serum ferritin on outcomes of patients with myelodysplastic syndromes or secondary acute myeloid leukaemia receiving reduced intensity conditioning allogeneic haematopoietic stem cell transplantation.
Leukemia research, 34 6
K. Naqvi, G. Garcia-Manero, S. Sardesai, J. Oh, C. Vigil, S. Pierce, X. Lei, J. Shan, H. Kantarjian, M. Suarez‐Almazor (2011)Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 16
G. Laport, B. Sandmaier, B. Storer, B. Scott, M. Stuart, T. Lange, M. Maris, E. Agura, T. Chauncey, R. Wong, S. Forman, F. Petersen, J. Wade, E. Epner, B. Bruno, W. Bethge, P. Curtin, D. Maloney, K. Blume, R. Storb (2008)Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 14 2
J. Guralnik, R. Eisenstaedt, L. Ferrucci, H. Klein, R. Woodman (2004)Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia.
Blood, 104 8
G. Garcia-Manero, J. Shan, S. Faderl, J. Cortes, F. Ravandi, G. Borthakur, W. Wierda, S. Pierce, E. Estey, Jingwei Liu, Xuelin Huang, H. Kantarjian (2008)A prognostic score for patients with lower risk myelodysplastic syndrome
R. Bejar, K. Stevenson, P. Stojanov, J. Zaneveld, M. Bar‐Natan, B. Caughey, Hui Wang, G. Garcia-Manero, H. Kantarjian, C. Cutler, J. Ritz, K. Cibulskis, G. Getz, D. Steensma, R. Stone, Rui Chen, D. Neuberg, B. Ebert (2012)Detection of Recurrent Mutations by Pooled Targeted Next-Generation Sequencing in MDS Patients Prior to Treatment with Hypomethylating Agents or Stem Cell Transplantation
A. Krishnan, M. Pasquini, B. Logan, E. Stadtmauer, D. Vesole, E. Alyea, J. Antin, R. Comenzo, S. Goodman, P. Hari, G. Laport, M. Qazilbash, S. Rowley, F. Sahebi, G. Somlo, D. Vogl, D. Weisdorf, M. Ewell, Juan Wu, N. Geller, M. Horowitz, S. Giralt, D. Maloney (2011)Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial.
The Lancet. Oncology, 12 13
P. Soubeyran, M. Fonck, C. Blanc-Bisson, J. Blanc, J. Ceccaldi, C. Mertens, Y. Imbert, L. Cany, L. Vogt, J. Dauba, Francis Andriamampionona, N. Houédé, A. Floquet, F. Chomy, V. Brouste, A. Ravaud, C. Bellera, M. Rainfray (2012)Predictors of early death risk in older patients treated with first-line chemotherapy for cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 15
Z. Lim, R. Brand, R. Martino, A. Biezen, J. Finke, A. Bacigalupo, D. Beelen, A. Devergie, E. Alessandrino, R. Willemze, T. Ruutu, M. Boogaerts, M. Falda, J. Jouet, D. Niederwieser, N. Kroger, G. Mufti, T. Witte (2010)Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 3
A. Brett (2007)Myelodysplastic Syndromes: Incidence and Survival
NEJM Journal Watch, 2007
U. Platzbecker, J. Schetelig, J. Finke, R. Trenschel, Bart Scott, G. Kobbe, K. Schaefer-Eckart, M. Bornhäuser, R. Itzykson, U. Germing, D. Beelen, G. Ehninger, P. Fenaux, H. Deeg, L. Adès (2012)Allogeneic hematopoietic cell transplantation in patients age 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidine.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 18 9
H. Kantarjian, J. Issa, C. Rosenfeld, J. Bennett, M. Albitar, J. Dipersio, V. Klimek, J. Slack, Carlos Castro, F. Ravandi, Richard Helmer, Lanlan Shen, S. Nimer, R. Leavitt, A. Raza, H. Saba (2006)Decitabine improves patient outcomes in myelodysplastic syndromes
L. Silverman, E. Demakos, B. Peterson, A. Kornblith, J. Holland, R. Odchimar-Reissig, R. Stone, D. Nelson, B. Powell, C. Decastro, J. Ellerton, R. Larson, C. Schiffer, J. Holland (2002)Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 10
L. Welniak, B. Blazar, W. Murphy (2007)Immunobiology of allogeneic hematopoietic stem cell transplantation.
Annual review of immunology, 25
M. Mohty, H. Lavallade, P. Ladaique, C. Faucher, N. Vey, D. Coso, Stoppa Am, J. Gastaut, D. Blaise (2005)The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison
P. Cassileth, D. Harrington, F. Appelbaum, H. Lazarus, J. Rowe, E. Paietta, C. Willman, D. Hurd, J. Bennett, K. Blume, D. Head, P. Wiernik (1998)Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission.
The New England journal of medicine, 339 23
J. Bennett, D. Catovsky, M. Daniel, G. Flandrin, D. Galton, H. Gralnick, H. Gralnick, C. Sultan (1982)Proposals for the classification of the myelodysplastic syndromes
British Journal of Haematology, 51
P. Greenberg, N. Young, N. Gattermann (2013)Myelodysplastic syndromes.
Hematology. American Society of Hematology. Education Program
R. Itzykson, S. Thépot, B. Quesnel, F. Dreyfus, C. Récher, E. Wattel, C. Gardin, L. Adès, P. Fenaux (2012)Long-term outcome of higher-risk MDS patients treated with azacitidine: an update of the GFM compassionate program cohort.
Blood, 119 25
J. Koreth, J. Pidala, W. Pérez, H. Deeg, G. Garcia-Manero, L. Malcovati, M. Cazzola, Sophie Park, R. Itzykson, L. Adès, P. Fenaux, M. Jädersten, E. Hellström-Lindberg, Robert Gale, Robert Gale, C. Beach, Stephanie Lee, M. Horowitz, P. Greenberg, Martin Tallman, Martin Tallman, J. Dipersio, D. Bunjes, D. Weisdorf, C. Cutler (2013)Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 21
B. Logan, E. Leifer, C. Bredeson, M. Horowitz, M. Ewell, S. Carter, N. Geller (2008)Use of biological assignment in hematopoietic stem cell transplantation clinical trials
Clinical Trials, 5
A. List, G. Dewald, J. Bennett, A. Giagounidis, A. Raza, E. Feldman, B. Powell, P. Greenberg, D. Thomas, R. Stone, C. Reeder, K. Wride, J. Patin, Michele Schmidt, J. Zeldis, R. Knight (2006)Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.
The New England journal of medicine, 355 14
R. Itzykson, O. Kosmider, T. Cluzeau, V. Mas, F. Dreyfus, O. Beyne-Rauzy, B. Quesnel, N. Vey, V. Gelsi-Boyer, S. Raynaud, C. Preudhomme, L. Adès, P. Fenaux, M. Fontenay (2011)Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias
MDS are myeloid clonal hematologic disorders that are most commonly diagnosed in the seventh decade of life. Several treatment options are currently available. However, allo HSCT remains the only curative therapy. Unfortunately, despite the higher incidence of MDS in the older population, less than 10 % of patients undergoing allo HSCT for MDS are > 65 years old. In this paper we discuss the various treatment options in older patients with high-risk MDS with particular emphasis on the role of allo HSCT in older MDS patients.
Current Hematologic Malignancy Reports – Springer Journals
Published: Jan 8, 2014
Access the full text.
Sign up today, get DeepDyve free for 14 days.